R. Colonno

发表

Characterization of a hemagglutinin-specific inhibitor of influenza A virus.

M. Krystal, G. Luo, R. Colonno, 1996, Virology.

Chimeric picornavirus polyproteins demonstrate a common 3C proteinase substrate specificity

B. Semler, R. Colonno, M. Lawson, 1989, Journal of virology.

Antigenic conservation and divergence between the viral-specific proteins of poliovirus type 1 and various picornaviruses.

E. Wimmer, W. Schleif, E. Emini, 1985, Virology.

Molecular cloning and complete sequence determination of RNA genome of human rhinovirus type 14.

S. Mizutani, R. Colonno, P. L. Callahan, 1985, Proceedings of the National Academy of Sciences of the United States of America.

In vitro synthesis of an infectious RNA from cDNA clones of human rhinovirus type 14

S. Mizutani, R. Colonno, 1985, Journal of virology.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Min Gao, Nicholas A. Meanwell, Lawrence G. Hamann, 2010, Nature.

Many rhinovirus serotypes share the same cellular receptor

R. Colonno, G. Abraham, Gordon ABRAHAMt, 1984, Journal of virology.

cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1.

J. Tomassini, R. Colonno, D. Lineberger, 1989, Proceedings of the National Academy of Sciences of the United States of America.

The major and minor group receptor families contain all but one human rhinovirus serotype.

R. Colonno, C. DeWitt, C. Uncapher, 1991, Virology.

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.

R. Colonno, R. Rose, D. Tenney, 2008, Journal of hepatology.

Inhibition of Hepatitis B Virus Polymerase by Entecavir

Ronald E. Rose, David R. Langley, D. Langley, 2007, Journal of Virology.

Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion.

N. Meanwell, D. Langley, C. Cianci, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Isolation of a receptor protein involved in attachment of human rhinoviruses

J. Tomassini, R. Colonno, 1986, Journal of virology.

Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses

R. Colonno, P. L. Callahan, W. Long, 1986, Journal of virology.

Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

L. Corey, I. Medina, J. Clark, 2001, The Journal of infectious diseases.

Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies.

L. Alexander, M. Krystal, R. Colonno, 2010, Virology.

Envelope Conformational Changes Induced by Human Immunodeficiency Virus Type 1 Attachment Inhibitors Prevent CD4 Binding and Downstream Entry Events

James E. Robinson, R. Colonno, P. Clapham, 2006, Journal of Virology.

Chapter 23 Selected New Developments in the Biochemistry of Viruses

R. Colonno, B. Korant, R. Lockart, 1979 .

Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase.

T. Chung, C. Cianci, M. Krystal, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (B

N. Meanwell, D. Langley, R. Colonno, 2013, Journal of medicinal chemistry.

Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

P. Angus, N. Warner, S. Locarnini, 2004, Antimicrobial Agents and Chemotherapy.

490 High barrier to resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapy

R. Colonno, R. Rose, D. Tenney, 2006 .

Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naive adults: 24 wk results (EARLY study)

A. Cross, M. Sherman, L. Lesmana, 2006 .

Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients

R. Colonno, Haitao Guo, Jian Sun, 2020, Hepatology.

The Amount of Hepatocyte Turnover That Occurred during Resolution of Transient Hepadnavirus Infections Was Lower When Virus Replication Was Inhibited with Entecavir

S. Litwin, Arend Grosse, R. Colonno, 2008, Journal of Virology.

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

N. Meanwell, R. Colonno, Chaoqun Chen, 2012, Antimicrobial Agents and Chemotherapy.

Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects

M. Krystal, R. Colonno, D. Grasela, 2010, Antimicrobial Agents and Chemotherapy.

Entecavir Exhibits Inhibitory Activity against Human Immunodeficiency Virus under Conditions of Reduced Viral Challenge

N. Parkin, M. Krystal, R. Colonno, 2008, Antimicrobial Agents and Chemotherapy.

Entecavir Exhibits Inhibitory Activity against Human Immunodeﬁciency Virus under Conditions of Reduced Viral Challenge (cid:1)

N. Parkin, M. Krystal, R. Colonno, 2008 .

Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4.

M. Abdel-hamid, A. Gomaa, I. Waked, 2017, Journal of hepatology.

Viral Hepatitis Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4 Graphical abstract

M. Abdel-hamid, A. Gomaa, I. Waked, 2017 .

Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.

L. Hamann, A. Fura, N. Meanwell, 2014, Journal of medicinal chemistry.

Virus receptors: the Achilles' heel of human rhinoviruses.

R. Colonno, 1992, Advances in experimental medicine and biology.

Differential effect of modified capped RNA substrates on influenza virus transcription.

C. Cianci, M. Krystal, R. Colonno, 1997, Virus Research.

Newcastle disease virus mRNA lacks 2′-O-methylated nucleotides

R. Colonno, H. O. Stone, RICHARD J. COLONNO, 1976, Nature.

Interferon induction of fibroblast proteins with guanylate binding activity.

R. Colonno, F. H. Yin, Y. Cheng, 1983, The Journal of biological chemistry.

A collaborative report: rhinoviruses--extension of the numbering system from 89 to 100.

W. S. Jordan, R. Colonno, M. Cooney, 1987, Virology.

Efficacy of the Carbocyclic 2′-Deoxyguanosine Nucleoside BMS-200475 in the Woodchuck Model of Hepatitis B Virus Infection

I. Medina, J. Clark, R. Colonno, 1998, Antimicrobial Agents and Chemotherapy.

Virus Infection in the Woodchuck Model of Hepatitis B-Deoxyguanosine Nucleoside BMS-200475 ′ Efficacy of the Carbocyclic 2

I. Medina, J. Clark, R. Colonno, 1998 .

Replication-Competent Chimeric Hepatitis C Virus Subgenomic Replicons

J. Lemm, R. Colonno, M. Gao, 2005, Intervirology.

The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons.

A. Lazzarin, K. Squires, R. Colonno, 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Characterization of human rhinoviruses displaced by an anti-receptor monoclonal antibody

R. Colonno, G. Abraham, 1988, Journal of virology.

Intervening polyadenylate sequences in RNA transcripts of vesicular stomatitis virus

R. Herman, H. Westphal, R. Colonno, 1978, Cell.

Domains 1 and 2 of ICAM-1 are sufficient to bind human rhinoviruses.

R. Colonno, D. Lineberger, D. Graham, 1992, Virus research.

Molecular Interactions between Human Rhinoviruses and the Adhesion Receptor ICAM-1

R. Colonno, 1992 .

Human-murine chimeras of ICAM-1 identify amino acid residues critical for rhinovirus and antibody binding

R. Colonno, D. Lineberger, C. Uncapher, 1991, Journal of virology.

Antibodies that block rhinovirus attachment map to domain 1 of the major group receptor

J. Tomassini, R. Colonno, D. Lineberger, 1990, Journal of virology.

Monoclonal antibody that inhibits infection of HeLa and rhabdomyosarcoma cells by selected enteroviruses through receptor blockade

W. Schleif, E. Emini, W. Long, 1986, Journal of virology.

Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus.

R. Sidwell, R. Colonno, J. Morrey, 2003, Antiviral research.

Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma Inhibition

R. Hamatake, C. Mazzucco, R. Colonno, 2007, Antimicrobial Agents and Chemotherapy.

Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors

J. Condra, D. Graham, E. Emini, 1992, Antimicrobial Agents and Chemotherapy.

Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.

N. Xia, M. McCrae, R. Colonno, 2016, Journal of hepatology.

Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731

R. Colonno, Yi Zhou, R. Yan, 2020, Antimicrobial Agents and Chemotherapy.

Bacterial expression of antibody fragments that block human rhinovirus infection of cultured cells.

J. Condra, D. Graham, J. Tomassini, 1990, Journal of Biological Chemistry.

Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir.

E. De Clercq, J. Neyts, R. Colonno, 2007, Antiviral research.

Different mRNAs induced by interferon in cells from inbred mouse strains A/J and A2G

P. Staeheli, R. Colonno, Y. Cheng, 1983, Journal of virology.

Effect of Antiviral Treatment with Entecavir on Age- and Dose-Related Outcomes of Duck Hepatitis B Virus Infection

R. Colonno, A. Jilbert, C. Scougall, 2005, Journal of Virology.

Biochemical characterization of a glycoprotein required for rhinovirus attachment.

J. Tomassini, R. Colonno, T. Maxson, 1989, The Journal of biological chemistry.

Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present

C. Mazzucco, R. Colonno, A. Walsh, 2006, Antimicrobial Agents and Chemotherapy.

CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B

A. Lok, R. Gish, R. Colonno, 2007 .

Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase

C. Cianci, R. Colonno, D. Tenney, 1997, Antimicrobial agents and chemotherapy.

Induction of unique mRNAs by human interferons.

R. Colonno, R. H. Pang, 1982, The Journal of biological chemistry.

Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.

Zheng Yang, Fang Zhao, Timothy P Spicer, 2003, Journal of medicinal chemistry.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity

N. Meanwell, R. Colonno, J. Kadow, 2009, Journal of medicinal chemistry.

BMS-200475, a novel carbocyclic 2′-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro

O. Kocy, M. Young, R. Colonno, 1997 .

Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro.

V. Garsky, R. Colonno, P. L. Callahan, 1990, The Journal of biological chemistry.

Cleavage of small peptides in vitro by human rhinovirus 14 3C protease expressed in Escherichia coli

V. Garsky, R. Colonno, P. L. Callahan, 1989, Journal of virology.

Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy

Ronald E. Rose, R. Colonno, R. Rose, 2009, Hepatology.

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

C. Mazzucco, R. Colonno, A. Walsh, 2006, Hepatology.

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.

E. Schiff, B. Bacon, R. Gish, 2005, Gastroenterology.

Development of Entecavir: Superior Therapy for the Management of Chronic Hepatitis B Viral Infection

A. Cross, R. Colonno, W. Fiske, 2004 .

In Vitro Inhibition of Hepadnavirus Polymerases by the Triphosphates of BMS-200475 and Lobucavir

R. Hamatake, R. Colonno, M. Seifer, 1998, Antimicrobial Agents and Chemotherapy.

BMS-200475 and Lobucavir Polymerases by the Triphosphates of In Vitro Inhibition of Hepadnavirus

R. Hamatake, R. Colonno, M. Seifer, 1998 .

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.

Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatitis B virus (HBV) infection.

I. Medina, J. Clark, R. Colonno, 2000, Antiviral research.

Development of a Cell-Based High-Throughput Specificity Screen Using a Hepatitis C Virus-Bovine Viral Diarrhea Virus Dual Replicon Assay

J. Lemm, R. Colonno, M. Gao, 2005, Antimicrobial Agents and Chemotherapy.

The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.

Qi Gao, Huabin Sun, Hong Shi, 2014, Journal of medicinal chemistry.

Identification of N-Hydroxamic Acid and N-Hydroxyimide Compounds that Inhibit the Influenza Virus Polymerase

T. Chung, N. Meanwell, C. Cianci, 1996 .

Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.

Chong-Hwan Chang, M. Witmer, B. Beno, 2014, Journal of medicinal chemistry.

Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability.

A. Marino, N. Meanwell, I. Medina, 2007, Bioorganic & medicinal chemistry letters.

Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.

S. Spergel, O. Kocy, J. Barrish, 1996, Journal of medicinal chemistry.

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

R. Colonno, M. Seifer, D. Standring, 1997, Antimicrobial agents and chemotherapy.

Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection

N. Meanwell, I. Medina, C. Cianci, 2004, Antimicrobial Agents and Chemotherapy.

Orally Active Fusion Inhibitor of Respiratory Syncytial Virus

N. Meanwell, I. Medina, C. Cianci, 2004, Antimicrobial Agents and Chemotherapy.

Mapping and initiation studies on the leader RNA of vesicular stomatitis virus.

R. Colonno, A. Banerjee, 1977, Virology.

Isolation of a transcriptive complex from Newcastle disease virions

R. Colonno, H. O. Stone, 1976, Journal of virology.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043)

N. Meanwell, R. Colonno, K. Yeung, 2012, Journal of medicinal chemistry.

Evidence for the direct involvement of the rhinovirus canyon in receptor binding.

M. Murcko, S. Mizutani, J. Condra, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis of complementary RNA containing polyadenylic acid by Sendai virions in vitro

R. Colonno, H. O. Stone, 1976, Journal of virology.

Methylation of messenger RNA of Newcastle disease virus in vitro by a virion-associated enzyme.

R. Colonno, H. O. Stone, 1975, Proceedings of the National Academy of Sciences of the United States of America.

43 Absence of entecavir resistance emergence in lamivudine-refractory patients treated for at least one year with entecavir in study A1463-014

A. Cross, R. Colonno, R. Hindes, 2004 .

Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro

R. J. Colonno, R. Colonno, R. Rose, 2002, Antimicrobial Agents and Chemotherapy.

Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus Replication

M. Winters, P. Marion, F. Salazar, 2002, Antimicrobial Agents and Chemotherapy.

Metabolic Studies on BMS-200475, a New Antiviral Compound Active against Hepatitis B Virus

P. Egli, R. Colonno, G. Bisacchi, 1999, Antimicrobial Agents and Chemotherapy.

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

A. Cross, A. Lok, R. Gish, 2006, The New England journal of medicine.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

Ching-Lung Lai, Anne Cross, A. Cross, 2006, The New England journal of medicine.

[49] ENTECAVIR (ETV) RESULTS IN HIGHER HBV-DNA REDUCTION VS ADEFOVIR (ADV) IN CHRONICALLY INFECTED HBeAg(+) ANTIVIRAL-NAIVE ADULTS: 48 WK RESULTS (E.A.R.L. STUDY)

A. Cross, M. Sherman, M. Yuen, 2007 .

Entecavir Therapy Combined with DNA Vaccination for Persistent Duck Hepatitis B Virus Infection

P. Marion, R. Colonno, A. Jilbert, 2003, Antimicrobial Agents and Chemotherapy.

Mechanistic Characterization and Molecular Modeling of Hepatitis B Virus Polymerase Resistance to Entecavir

D. Langley, R. Colonno, A. Walsh, 2010, PloS one.

Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.

D. Miller, R. Colonno, D. Boyle, 2008, Virology.

Ultrasensitive Genotypic Detection of Antiviral Resistance in Hepatitis B Virus Clinical Isolates

C. Mazzucco, B. Kienzle, R. Colonno, 2009, Antimicrobial Agents and Chemotherapy.

Entecavir at Five Years Shows Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance

R. Colonno, R. Rose, D. Tenney, 2008 .

Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.

M. Yuen, D. J. Kim, K. Agarwal, 2019, The lancet. Gastroenterology & hepatology.

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

A. Lok, R. Gish, Shou-Dong Lee, 2007, Gastroenterology.

366 Combination studies involving entecavir and HIV nucleoside reverse transcriptase inhibitors showed no antagonistic effects on HBV or HIV activity in vitro

R. Colonno, L. Discotto, S. Weinheimer, 2004 .

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance

C. Mazzucco, R. Colonno, R. Rose, 2008, Hepatology.

Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase

N. Meanwell, J. Lemm, R. Colonno, 2014, Antimicrobial Agents and Chemotherapy.

33 IDENTIFICATION AND CHARACTERIZATION OF PPI-461, A POTENT AND SELECTIVE HCV NS5A INHIBITOR WITH ACTIVITY AGAINST ALL HCV GENOTYPES

R. Colonno, N. Huang, J. Williams, 2010 .

Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.

Neil Parkin, N. Parkin, R. Colonno, 2004, The Journal of infectious diseases.

Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors

N. Parkin, R. Colonno, K. Limoli, 2003, Antimicrobial Agents and Chemotherapy.

Substituted naphthalenones as a new structural class of HIV-1 reverse transcriptase inhibitors.

R. Colonno, A. Patick, A. Meyers, 1993, Antiviral research.

De Novo Initiation of RNA Synthesis by the RNA-Dependent RNA Polymerase (NS5B) of Hepatitis C Virus

R. Hamatake, J. Lemm, G. Luo, 2000, Journal of Virology.

Oligopeptides inhibit the ribonucleotide reductase of herpes simplex virus by causing subunit separation.

W. Mcclements, V. Garsky, S. Bacchetti, 1988, Virology.

Characterization of monoclonal antibodies recognizing amino- and carboxy-terminal epitopes of the herpes simplex virus UL42 protein.

R. Hamatake, R. Colonno, D. Tenney, 1995, Virus research.

Characterization of vesicular stomatitis virus mRNA species synthesized in vitro

W. Jelinek, R. Colonno, A. Banerjee, 1977, Journal of virology.

Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication

T. Chou, R. Colonno, T C Chou, 1996, Antimicrobial agents and chemotherapy.

Modification of experimental rhinovirus colds by receptor blockade.

F. Hayden, R. Colonno, J. Gwaltney, 1988, Antiviral research.

Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy

V. Calvez, M. Wainberg, V. Soriano, 1999, Antiviral therapy.

Effect of 2'-nor-cyclic GMP against guinea pig cytomegalovirus infection

R. Colonno, R. Tolman, H. Lucia, 1989, Antimicrobial Agents and Chemotherapy.

O65 HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN

R. Colonno, J. Lalezari, N. Huang, 2014 .

Molecular Basis for Increased Susceptibility of Isolates with Atazanavir Resistance-Conferring Substitution I50L to Other Protease Inhibitors

Michael L. Doyle, Ronald E. Rose, David R. Langley, 2005, Antimicrobial Agents and Chemotherapy.

Atazanavir Signature I50L Resistance Substitution Accounts for Unique Phenotype of Increased Susceptibility to Other Protease Inhibitors in a Variety of Human Immunodeficiency Virus Type 1 Genetic Backbones

R. Colonno, L. Discotto, J. Friborg, 2005, Antimicrobial Agents and Chemotherapy.

BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents

David A. Stock, R. Colonno, W. Blair, 2000, Antimicrobial Agents and Chemotherapy.

α-hydroxyamide derived aminodiols as potent inhibitors of hiv protease

Ping Chen, S. Spergel, J. Barrish, 1995 .

Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus

N. Meanwell, C. Cianci, M. Krystal, 1997, Journal of virology.

Complete nucleotide sequence of the leader rna synthesized in vitro by vesicular stomatitis virus

R. Colonno, A. Banerjee, 1978, Cell.

A unique RNA species involved in initiation of vesicular stomatitis virus RNA transcription in vitro

R. Colonno, A. Banerjee, 1976, Cell.

Vesicular stomatitis virus: mode of transcription.

R. Colonno, A. Banerjee, G. Abraham, 1977, The Journal of general virology.

In vitro RNA transcription by the New Jersey serotype of vesicular stomatitis virus. II. Characterization of the leader RNA

R. Colonno, A. Banerjee, 1978, Journal of virology.

In vitro synthesis of messenger RNA by a defective interfering particle of vesicular stomatitis virus.

J. Keene, R. Colonno, R. Lazzarini, 1977, Proceedings of the National Academy of Sciences of the United States of America.

Nucleotide sequence oftheleader RNAoftheNewJersey serotype ofvesicular stomatitis virus

R. Colonno, 1978 .

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion

John P. Moore, T. Ketas, R. Veazey, 2005, Nature.

The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth

W. Newcomb, J. Brown, S. F. Ditusa, 1994, Journal of virology.

Identification of the herpes simplex virus-1 protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products.

I. Deckman, M. Cordingley, B. Roizman, 1993, The Journal of biological chemistry.

Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 Interactions

N. Meanwell, D. Langley, R. Colonno, 2003, Journal of Virology.

Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors.

R. Colonno, Qi Huang, N. Huang, 2014, Bioorganic & medicinal chemistry letters.

In Vivo Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043

D. Langley, L. Alexander, M. Krystal, 2010, Antimicrobial Agents and Chemotherapy.

Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.

N. Meanwell, D. Langley, R. Colonno, 2018, Journal of medicinal chemistry.

Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor

R. Colonno, A. Patick, R. White, 1996, Antimicrobial agents and chemotherapy.

Identification of Hepatitis C Virus NS5A Inhibitors

N. Meanwell, M. Deshpande, Scott W. Martin, 2009, Journal of Virology.

Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

R. Colonno, R. Rose, B. Terry, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs.

R. Colonno, Qi Huang, N. Huang, 2014, Bioorganic & medicinal chemistry letters.

Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.

R. Colonno, Qi Huang, N. Huang, 2016, Bioorganic & medicinal chemistry letters.

Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments

J. Tomassini, R. Rueckert, R. Colonno, 1989, Journal of virology.

Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14

B. Sherry, A. Mosser, R. Rueckert, 1986, Journal of virology.

Cell surface receptors for picornaviruses

R. Colonno, 1986, BioEssays : news and reviews in molecular, cellular and developmental biology.

Final Results of the Pyramid 1 Study, a Phase 3 Registrational Trial of Ravidasvir (PPI-668) and Sofosbuvir in HCV Genotype-4 Patients: High Rates of Sustained Viral Clearance in Cirrhotic and Non-Cirrhotic Patients

M. Abdel-hamid, A. Gomaa, I. Waked, 2016 .

In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632

Timothy P. Spicer, Ronald E. Rose, T. Spicer, 2000, Antimicrobial Agents and Chemotherapy.

Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor

J. Barrish, M. Hermsmeier, R. Colonno, 1995, Journal of virology.

Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy.

R. Colonno, R. Rose, H. Samanta, 1998, AIDS.

Characterization of a Mutant HIV-1 Reverse Transcriptase Resistant to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150)

R. Colonno, A. Patick, R. Rose, 1994 .

Specific Inhibition of Bovine Viral Diarrhea Virus Replicase

J. Lemm, R. Colonno, M. Gao, 2003, Journal of Virology.

Separate functional domains of the herpes simplex virus type 1 protease: evidence for cleavage inside capsids

W. Newcomb, J. Brown, R. Colonno, 1996, Journal of virology.

Interaction of a limited set of proteins with different mRNAs and protection of 5'-caps against pyrophosphatase digestion in initiation complexes

Nahum Sonenberg, M. A. Morgan, D. Testa, 1979, Nucleic Acids Res..

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

Zheng Yang, Tao Wang, Robert Fridell, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.

R. Colonno, Qi Huang, N. Huang, 2018, Bioorganic & medicinal chemistry letters.

Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.

A. Marino, N. Meanwell, R. Colonno, 2010, Journal of pharmaceutical sciences.

Preclinical pharmacokinetics of a novel HIV‐1 attachment inhibitor BMS‐378806 and prediction of its human pharmacokinetics

A. Marino, N. Meanwell, R. Colonno, 2005, Biopharmaceutics & drug disposition.

Establishment of an in vitro assay to characterize hepatitis C virus NS3-4A protease trans-processing activity.

R. Hamatake, H. Wang, R. Colonno, 1996, Intervirology.

Avian cells expressing the murine Mx1 protein are resistant to influenza virus infection.

J. Condra, R. Colonno, E. Garber, 1991, Virology.

Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns.

T. Spicer, N. Meanwell, P. Shi, 2009, Bioorganic & medicinal chemistry letters.

Stimulation of the Herpes Simplex Virus Type I Protease by Antichaeotrophic Salts (*)

I. Deckman, R. Colonno, S. Weinheimer, 1995, The Journal of Biological Chemistry.

Identification of the serine residue at the active site of the herpes simplex virus type 1 protease.

R. Colonno, S. Weinheimer, D. O’Boyle, 1994, The Journal of biological chemistry.

pH-Dependent Changes in Photoaffinity Labeling Patterns of the H1 Influenza Virus Hemagglutinin by Using an Inhibitor of Viral Fusion

N. Meanwell, M. Deshpande, C. Cianci, 1999, Journal of Virology.

PS-073-Preclinical profile of HBV core protein inhibitor, ABI-H, a potent inhibitor of cccDNA generation in HBV infected cells

M. Bures, R. Colonno, Yi Zhou, 2019, Journal of Hepatology.

Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.

Hui Li, R. E. Anderson, R. Colonno, 1994, The Journal of infectious diseases.

Structural Analysis of the Native and Drug Resistant HIV-1 Proteinases Complexed With an Aminodiol Inhibitor

Alexander Wlodawer, Jukka Kervinen, Pin-Fang Lin, 1996, Protein & Peptide Letters.

Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B

M. Yuen, K. Agarwal, R. Colonno, 2018 .

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

A. Cross, A. Lok, R. Gish, 2006, The New England journal of medicine.

ManyRhinovirus Serotypes SharetheSameCellular Receptor

R. Colonno, 1984 .

LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients

E. Schiff, T. Hassanein, M. Yuen, 2019, Journal of Hepatology.

Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.

R. Colonno, A. Jilbert, F. Feng, 2008, Virology.

Autoproteolysis of herpes simplex virus type 1 protease releases an active catalytic domain found in intermediate capsid particles

I. Deckman, M. Cordingley, B. Roizman, 1993, Journal of virology.

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.